Tarsus Pharmaceuticals, Inc.
TARS
$68.90
$0.941.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -66.42M | -81.16M | -91.99M | -104.94M | -115.55M |
| Total Depreciation and Amortization | 1.82M | 1.81M | 1.63M | 1.42M | 1.23M |
| Total Amortization of Deferred Charges | 593.00K | 575.00K | 552.00K | 507.00K | 482.00K |
| Total Other Non-Cash Items | 36.92M | 29.48M | 25.02M | 26.61M | 26.98M |
| Change in Net Operating Assets | 14.64M | -4.66M | -16.08M | 10.52M | 3.84M |
| Cash from Operations | -12.45M | -53.96M | -80.87M | -65.89M | -83.03M |
| Capital Expenditure | -9.86M | -3.57M | -1.95M | -1.98M | -1.57M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -32.26M | -147.39M | -141.15M | -129.93M | -197.63M |
| Cash from Investing | -42.12M | -150.96M | -143.09M | -131.91M | -199.20M |
| Total Debt Issued | -- | 0.00 | 0.00 | 75.00M | 75.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 143.39M | 144.00M | 142.12M | 142.85M | 105.69M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | -39.00K | -35.40M | -26.04M |
| Cash from Financing | 143.39M | 144.00M | 142.08M | 182.45M | 154.66M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 88.82M | -60.92M | -81.88M | -15.36M | -127.57M |